REVB (Revelation Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Revelation Biosciences, Inc. Common Stock (REVB) is a publicly traded Healthcare sector company. As of May 21, 2026, REVB trades at $1.09 with a market cap of $4.06M and a P/E ratio of -0.04. REVB moved +0.00% today. Year to date, REVB is -67.52%; over the trailing twelve months it is -96.38%. Its 52-week range spans $0.88 to $241.92. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces REVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns REVB stock?
Hedge funds tracked by Rallies that own REVB include Two Sigma and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Revelation Biosciences, Inc. Common Stock.
REVB Key Metrics
Key financial metrics for REVB
Metric
Value
Price
$1.09
Market Cap
$4.06M
P/E Ratio
-0.04
EPS
$-23.95
Dividend Yield
0.00%
52-Week High
$241.92
52-Week Low
$0.88
Volume
0
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-8.91M
Gross Margin
0.00%
Top Hedge Funds Holding REVB
Two Sigma holds 29.10K shares of REVB, changed +0.00% as of Dec 31, 2024.
Citadel Advisors holds 24.14K shares of REVB, changed +0.00% as of Dec 31, 2023.
Hedge funds tracked by Rallies that own REVB include Two Sigma and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Revelation Biosciences, Inc. Common Stock.
Does Rallies show 13F holders for REVB?
Yes. Rallies tracks hedge fund and 13F ownership data for REVB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is REVB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for REVB. It does not provide personalized investment advice.
